Search research articles
Contact Us
Filters
Showing results (121-130 of 207) with videos related to
Page
of 21
Sort By:
Clinical Sarcoma Research
|
August 19, 2014
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
Thomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
Grant A McArthur, George D Demetri, Allan van Oosterom, et al.
Cancers
|
December 10, 2021
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial
Che-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Gastroenterology
|
November 8, 2006
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA
Thomas de Raedt, Jan Cools, Maria Debiec-Rychter, et al.
Molecular Cancer Therapeutics
|
June 2, 2017
<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Jasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, et al.
Molecular Cancer Therapeutics
|
October 26, 2016
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
Yemarshet K Gebreyohannes, Patrick Schöffski, Thomas Van Looy, et al.
Plos One
|
June 5, 2012
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
Joern Henze, Thomas Mühlenberg, Susanne Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2008
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, et al.
The American Journal of Surgical Pathology
|
November 7, 2008
Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs
Jean-François Emile, Nathalie Stock, Christopher L Corless, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy
Thomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Page
of 21
Search research articles
Search
Showing results (121-130 of 207) with videos related to
Sort By:
Page
of 21
Clinical Sarcoma Research
|
August 19, 2014
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
Thomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2005
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
Grant A McArthur, George D Demetri, Allan van Oosterom, et al.
Cancers
|
December 10, 2021
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial
Che-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Gastroenterology
|
November 8, 2006
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA
Thomas de Raedt, Jan Cools, Maria Debiec-Rychter, et al.
Molecular Cancer Therapeutics
|
June 2, 2017
<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Jasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, et al.
Molecular Cancer Therapeutics
|
October 26, 2016
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
Yemarshet K Gebreyohannes, Patrick Schöffski, Thomas Van Looy, et al.
Plos One
|
June 5, 2012
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
Joern Henze, Thomas Mühlenberg, Susanne Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2008
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, et al.
The American Journal of Surgical Pathology
|
November 7, 2008
Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs
Jean-François Emile, Nathalie Stock, Christopher L Corless, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy
Thomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Page
of 21